Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet needLONDON, Dec. 27, 2022...
New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that,...
Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET) Nexstim Plc’s Financial Information in 2023 Nexstim Plc (NXTMH:HEX, NXTMS:STO)...
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is...
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural...
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE)...
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...
Company Announcement, Helsinki, 17 December 2022 at 7.15 PM (EET) Nexstim Plc: Changes in the management team – Henri Hannula...
Brain Power Wellness invests in its most valuable resource - its employees - with a new expanded time off policy.NEW...
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022...
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13,...
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease...
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented...
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...